Back to top
more

Oculis Holding AG (OCS)

(Delayed Data from NSDQ)

$18.20 USD

18.20
7,073

+0.36 (2.02%)

Updated Aug 6, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of +112.50% and +344.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -50.98% and 42.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -58.33% and 98.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going

by Zacks Equity Research

Oculis Holding AG (OCS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Oculis Holding AG (OCS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -5.77% and 11.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of -36.82% and 42.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of -5% and 1.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?

by Zacks Equity Research

Oculis Holding AG (OCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -30.23% and 3.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -2,733.33% and 97.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -28.43% and 98.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aadi Bioscience (AADI) delivered earnings and revenue surprises of 23.94% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%

by Zacks Equity Research

The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Oculis Holding AG (OCS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 191.3% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.